Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01054599 · ClinicalTrials.gov registry record · NA
Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
A NA study of Epilepsy, sponsored by American Academy of Neurology.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT01054599 is a NA study of Epilepsy that has completed, run by American Academy of Neurology. The registered enrollment target is 29 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01054599, a NA study of Epilepsy, has completed, sponsored by American Academy of Neurology.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
Many patients with epilepsy have memory deficits in the setting of otherwise normal intelligence. Unfortunately, the treatment options for memory dysfunction in patients with epilepsy are limited. The investigators are conducting a study to evaluate the effects of memantine for the treatment of verbal memory dysfunction in subjects with localization-related seizures. The study involves randomization to memantine therapy or placebo, with cognitive testing and EEG pre- and post-treatment, as well as after an open-label memantine treatment phase. The primary aim of this study is to evaluate the efficacy of memantine for the treatment of verbal memory dysfunction in subjects with left temporal lobe epilepsy. The investigators expect that verbal memory task performance will improve in those taking memantine, but not in those taking a placebo. The investigators propose that the expected benefit of memantine is specific to verbal memory in subjects with left temporal lobe seizures, rather than representing an overall improvement in cognitive function. The investigators expect no improvement on other cognitive tasks in either the memantine or placebo groups. The investigators will evaluate whether subjects with left temporal lobe epilepsy and memory difficulties have self-reported improvement in memory while taking memantine. The investigators expect improvement of self-rated memory function on the Quality of Life in Epilepsy Patient Inventory (QOLIE-89) in the memantine group, but no change on this scale in the placebo group.
Conditions Studied
Interventions
- DRUG Memantine
- OTHER Sugar Pill
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Newton-Wellesley Hospital - Newton
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01054599
The ClinicalTrials.gov registry entry for NCT01054599 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is American Academy of Neurology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Memantine is the first listed.
NCT01054599 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Georgia.
Frequently Asked Questions
What is clinical trial NCT01054599 about?
NCT01054599 is a clinical study titled "Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?". Many patients with epilepsy have memory deficits in the setting of otherwise normal intelligence. Unfortunately, the treatment options for memory dysfunction in patients with epilepsy are limited. The investigators are conducting a study to evaluate the effects of memantine for the treatment of verb...
What is the current status of trial NCT01054599?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2009-01. Estimated completion is 2014-05.
What conditions does trial NCT01054599 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT01054599?
The interventions under investigation include: Memantine (DRUG), Sugar Pill (OTHER).
Who is sponsoring clinical trial NCT01054599?
This trial is sponsored by American Academy of Neurology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01054599 being conducted?
This trial has 3 study locations across Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SeizEAR Safety Study
RECRUITING · NA
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
-
Subcortical Arousal in Perceptual Awareness
RECRUITING · NA
-
Prediction of Anxiety and Memory State
RECRUITING · NA
-
Implementation and Cost Evaluation of Project UPLIFT
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.